VIRxSYS Corporation Report issue

For profit Phase 2
Founded: Gaithersburg MD United States (1998)
Status: Defunct (2012)

Organization Overview

First Clinical Trial
2005
NCT00131560
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2007

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 2 Trials (1)

vrx496-modified autologous t cells (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

HIV Infections (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 1